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Abstract
Serrated pathway polyps are a relatively new area of interest in the field of colorectal cancer 
screening and prevention. Akin to conventional adenomas, some serrated polyps (SPs) have the 
potential to develop into malignant serrated neoplasms, yet little is known regarding risk factors 
for these lesions. Early epidemiological studies of hyperplastic polyps (HPs) were performed 
without knowledge of the serrated pathway, and likely included a mixture of SPs. More recently, 
studies have specifically evaluated premalignant SPs, such as the sessile serrated adenoma (SSA) 
or surrogates for these polyps such as large or proximally-located SPs. SPs share some risk factors 
with conventional adenomas, and have been associated with tobacco use, obesity, and age. 
Nonsteroidal anti-inflammatory drug (NSAID) use, fiber, folic acid, and calcium have been 
associated with reduced risk of SPs. Studies focused on SSAs specifically have reported 
associations with age, female sex, smoking, obesity, diabetes, and possibly diets high in fat, 
carbohydrates, and calories. Higher education has also been associated with risk of SSAs, while an 
inverse association between NSAID use and SSAs has been reported. Risk factors for traditional 
serrated adenomas (TSAs) are largely unknown. Studies are largely limited by varying inclusion 
criteria, as well as differences in pathological classification schemes. Further epidemiological 
studies of SPs are needed to aid in risk stratification and screening, and etiological research.
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Introduction
Serrated neoplasia is a relatively recent concept in the field of colorectal cancer 
pathogenesis. While knowledge of “hyperplastic” or “metaplastic” polyps of the colorectum 
has existed for over 50 years, these lesions were traditionally thought to be common yet 
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harmless mucosal lesions without potential for progression [1]. It is now recognized that 
some polyps previously classified as benign HPs included more dangerous lesions, such as 
sessile serrated adenomas (SSAs) and traditional serrated adenomas (TSAs), which are 
important precursor lesions in the development of serrated pathway carcinomas. Serrated 
polyps (SPs) are thus a heterogeneous family of colorectal polyps that do pose a risk of 
malignant transformation.
SSAs are typically located in the proximal colon and are flat and subtle lesions that can be 
difficult to detect during colonoscopy [2, 3]. As such, SSAs may be missed and resected 
incompletely by endoscopists [4-6]. Additionally, multiple lines of evidence suggest that 
serrated pathway precursors contribute to the problem of interval cancers, which is an 
important concern for gastroenterologists and patients alike [7-12]. Furthermore, there is 
evidence that proximal SPs pose a greater risk of metachronous neoplasia than tubular 
adenomas, indicating their importance in screening and surveillance [13].
However, SPs have only recently been addressed by surveillance guidelines [14]. 
Furthermore, despite their importance, the epidemiology of serrated pathway polyps is 
relatively understudied compared to conventional adenomas. The aim of this review is to 
highlight several of the previous epidemiological studies that have been performed regarding 
SPs, and to identify established risk factors, and those that merit further research. Ultimately, 
a better understanding of the epidemiology of these important CRC precursors could help 
tailor screening and surveillance recommendations and inform etiological basic science 
research.
Overview of the Serrated Pathway and Serrated Polyp Types
Serrated pathway
Until relatively recently, it was thought that conventional adenomas were the sole precursors 
to sporadic CRC, as they contained dysplastic tissue and had the potential for malignant 
transformation via the well-characterized adenoma-carcinoma sequence involving genetic 
mutations in KRAS, p53, and APC genes [15]. However, within the last two decades it has 
been shown that certain SPs have the potential to develop into CRC as well. SSAs and TSAs 
are considered to be the primary precursors to serrated pathway cancers [10, 16-21]. The 
progression from SSA or TSA to CRC involves different molecular features than the 
adenoma-carcinoma sequence, such as BRAF mutation, CpG island methylation (CIMP), 
and microsatellite instability (MSI) [22]. As with the adenoma-carcinoma sequence, it is 
likely that risk factors act at different steps along the serrated pathway (Figure 1).
Description of serrated polyps
SPs are identified histologically as having a “saw-toothed” appearance of crypt epithelium. 
The World Health Organization subclassifies SPs into three categories: HPs, SSAs (with or 
without cytological dysplasia), and TSAs (with or without conventional dysplasia) 
depending primarily on the crypt architecture [23]. HPs are the most prevalent of the group 
and make up 75%-95% of SPs, while SSAs make up less than ¼ of SPs, and TSAs are much 
rarer than SSAs, comprising only about 1% of SPs [24-29].
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HPs tend to be small (1 to 5mm) and distally-located, and have little or no risk of malignant 
potential [30-33]. HPs can be further classified into three subtypes: Microvesicular 
Hyperplastic Polyps (MVHP), Goblet Cell Hyperplastic Polyps (GCHP), and Mucin-Poor 
Hyperplastic Polyps (MPHP). While HPs as a group are not thought to have direct malignant 
potential, it is important to note that MVHPs exhibit molecular features (e.g. BRAF 
mutation) that are common to the premalignant SSA, and thus some have postulated that 
MVHPs may develop into SSAs and serrated pathway cancers, but this has not been 
definitively proven [10, 22, 34, 35].
SSAs represent 10-25% of all SPs [24, 25], are commonly located in the right colon, and are 
typically larger than HPs [26, 27]. SSAs are characterized histologically by distorted and 
dilated crypt bases, which resemble a boot-shaped pattern on cross-sectioning [22]. In 
contrast to adenomas, SSAs do not typically harbor dysplastic cells, but do have the 
potential to develop dysplasia and progress to malignancy [36]. The main route to malignant 
progression for SSAs involves CIMP-related inactivation of the hMLH1 gene, which leads 
to microsatellite instability and (probably) rapid growth, the development of cytological 
dysplasia, and malignant transformation into an MSI-high serrated carcinoma [3, 10, 35, 37] 
(Figure 1). It is worth noting that there remains controversy as to the best name for this 
lesion, and some authors prefer alternative terms such as “sessile serrated polyp.” 
Furthermore, due to issues of inconsistent pathological interpretation and changing 
nomenclature and taxonomy, some studies use surrogate definitions of important SPs such as 
proximal or large (typically ≥ 1 cm) SPs.
TSAs are the rarest form of SP, and are typically located in the distal colorectum [38]. TSAs 
resemble conventional adenomas, with a characteristic polypoid or pedunculated shape, 
though they are histologically distinct [2, 39, 40]. They contain conventional dysplasia more 
often than SSAs; however, the risk of progression to malignancy, as well as the time course 
of its progression is less certain given their rarity [28, 40].
Methods
To perform this review, we searched the MEDLINE-indexed medical literature using the 
PubMed search engine (http://www.pubmed.gov). The initial search string used was: 
(Epidemiology OR Risk Factor OR lifestyle) AND (Hyperplastic OR Serrated) AND polyps 
AND (colon OR colorectal). The results were limited to English language studies performed 
after 1990, and reviewed individually to identify relevant articles. Bibliographies of related 
articles were also reviewed to identify other pertinent studies.
Specific Risk Factors
Not surprisingly, studies analyzing risk factors for SSAs and TSAs are limited, given that the 
serrated pathway is still a burgeoning area of research, and many studies predate its 
inception. In fact, most epidemiologic studies regarding SPs performed prior to 2010 
grouped all SPs under the heading “hyperplastic polyps” and did not recognize the different 
subclasses of SPs. Furthermore, studies on HPs or SPs in general largely fail to distinguish 
between those that are located proximally or distally in the colorectum, or large vs. small 
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SPs. Nevertheless, several important studies of the epidemiology and risk factors of SPs will 
be reviewed here.
As a large number of early studies classified polyps as either adenomatous or hyperplastic, 
risk factors previously reported for hyperplastic polyps may better be generalized to SPs 
given its broader scope [33, 41-47]. It is likely that a small proportion of the “HPs” included 
in older studies (particularly large and/or proximally located HP) would be classified as 
SSAs based on the current pathologic criteria and nomenclature. However, it is also worth 
noting that prior to 5 years ago, the significance and endoscopic features of SSAs was not 
widely recognized, and therefore these lesions may have been less commonly identified or 
fully removed by endoscopists, so earlier studies likely included mostly distal HPs. For this 
reason, more contemporary studies are most informative with respect to the epidemiology of 
premalignant SPs. To date, there have been only two studies that specifically identified 
multiple risk factors for subclasses of SPs, particularly SSAs [48, 49]. Very little has been 
published on risk factors for TSAs.
Age
Older age is a major risk factor for development of conventional adenomas [50], and results 
have generally been similar in population-based studies of SPs. A German study reported an 
increased risk of HPs in those older than 55 years of age (age >55 vs. ≤55 years: OR 1.72, 
95% CI 1.00, 2.96) [42] while a Japanese study reported similar results (age 55-64 vs. ≤44 
years: OR 2.06, 95% CI 1.13, 3.78; age ≥65 vs. ≤44 years: OR 2.90, 95% CI 1.60, 5.30) [46] 
(Table 1). Two studies reported increased risk of SPs among individuals older than 50 years 
of age: Bouwens et al. (Age >50 vs. ≤50 years: OR 2.2, 95% CI 1.3, 3.8) and Burnett-
Hartman et al. (age 50-59 vs. <50 years: OR 1.87, 95% CI 1.20, 2.91) [48, 51].
With respect to SSAs and age, published data are limited. A large pathology series of over 
2000 patients with SSAs reported that the median age of those with SSAs was 62 years, 
which was the same as the median age of those with tubular adenomas [26]. Anderson et al. 
reported increasing risk of SSAs with age (per year increase in age: OR 1.05, 95% CI 1.02, 
1.08) [49]. Similarly, Burnett-Hartmann et al. reported an elevated risk of SSAs with 
advanced age, but this did not reach statistical significance, perhaps due to small stratum 
size. (age ≥70 vs. <50 years: OR 2.19, 95% CI 0.83, 5.76) [48]. However, other studies have 
reported null associations between age and SSAs or advanced serrated lesions [5, 52]. 
Additional studies are therefore needed to clarify whether ageing clearly increases the risk of 
SSAs, but it appears that age is not as strong of a risk factor for SPs as it is for conventional 
adenomas.
Sex
Sex is one of the strongest known risk factors for adenomatous polyps, which are more 
common in men [53-55]. Regarding all SPs, there have been mixed results regarding 
predisposition based on sex. Men were found to have an increased risk of SPs by Erhardt et 
al. (OR 1.83, 95% CI 1.05, 3.18), just as women were found to have decreased risk of SPs 
by Morimoto et al. (OR 0.6, 95% CI 0.5, 0.9) [42, 45] (Table 2). However, other studies have 
not shown any significant association between sex and SPs, including Omata et al. (male OR 
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1.54, 95% CI 0.97, 2.44), Min et al. (male OR 1.82, 95% CI 0.99, 3.32), Bouwens (male OR 
0.9, 95% CI 0.6, 1.2), Burnett-Hartman (female OR 1.06, 95% CI 0.8, 1.4), and Wallace 
(female proximal OR 1.07 95% CI 0.82, 1.39) [48, 51, 52, 56].
With regards to SSAs specifically, studies have also been mixed regarding sex-related risk. 
Burnett Hartman et al. (n = 149 SSAs) found that women were not at a statistically 
significant increased risk of SSAs (OR 1.37, 95% CI 0.82, 2.28), similar to Wallace et al. 
(proximal advanced serrated lesion RR 1.16, 95% CI 0.72, 1.87) [48, 52]. Similarly, in an 
average risk screening cohort, Hetzel et al. found that an equal proportion of men and 
women (50% each) had SSAs, and sex was not independently associated with SSA detection 
(male OR: 1.55, 95% CI 0.93, 2.61) [5]. However, a much larger study performed by Lash et 
al. examined 179,111 patients who had polyps removed on colonoscopy, and identified a 
sample of 2416 SSAs. Fifty-four percent of SSAs were found in women, and the authors did 
report an association between SSAs and female sex (OR 1.21, 95% CI 1.11, 1.32) [26]. 
Notably, this study also found that the female:male ratio increases as SSAs progress, as 
women made up 53% of those with nondysplastic SSAs, but 57%, 69%, and 76% of those 
with SSAs with low grade dysplasia, high grade dysplasia, and cancer respectively. A 
number of other studies have reported that a higher proportion of SSAs are removed from 
women, including Carr et al. (65% female) and Spring et al. (65% female) [24, 25]. It 
appears that there is a slight female predominance for SPs and SSAs in particular, and the 
sex distribution of SPs certainly differs from that of adenomas, where male sex is a clear risk 
factor.
Race and Ethnicity
African Americans have higher incidence of both colorectal adenomas and CRC [57, 58], 
but this does not appear to be true for SPs. In one US study, African Americans and 
Hispanics had lower risks of SPs compared to non-Hispanic whites (RR 0.65, 95% CI 0.50, 
0.85 and RR 0.33, 95% CI 0.20, 0.55, respectively) [52]. Similarly, another study reported a 
decreased risk of SPs in African Americans versus Caucasians, although not statistically 
significant (OR 0.49 95% CI: 0.23, 1.02) [48]. There have been a number of studies of 
serrated polyps in Japanese and other East Asian populations, but direct comparisons to 
other racial groups are limited [2, 56, 59]. With respect to SSAs specifically, the data are 
limited as well. Similar to the data for SPs in general, two studies have reported lower, but 
not statistically-significant associations between black race and SSAs or advanced SPs 
(Supplementary Table 3) [48, 52]. It is worth noting that the association between race and 
SPs appears quite strong based on point estimates, yet small numbers of non-whites in these 
studies likely limited the statistical power for these comparisons.
Socioeconomic status
Two early studies did not find a significant correlation between education level and presence 
of SPs [41, 45] (Supplementary Table 1). More recently, however, Burnett-Hartman et al. 
reported a positive association with SPs and higher education (college graduates vs. high 
school or less: OR 1.66, 95% CI 1.14, 2.43; graduate degree vs. high school or less: OR 
1.46, 95% CI 1.00, 2.12) [48]. The effect of higher education appeared to be slightly 
stronger for proximal vs. distal SPs, but this difference was not statistically significant 
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(Supplementary Table 2). Interestingly, a stronger association was reported between higher 
education and SSAs specifically (college graduates vs. high school or less: OR 3.35, 95% CI 
1.41, 7.99; graduate degree vs. high school or less: OR 3.63, 95% CI 1.55, 8.54) 
(Supplementary Table 3). Given the lack of a plausible biologic link between higher 
education and serrated neoplasia, it is possible that this effect is confounded by other factors, 
such as quality of bowel preparation, race, diet, or access to care. Due to the lack of other 
corroborating studies on this and other socioeconomic risk factors, this area certainly 
deserves more consideration in the future.
Smoking
Tobacco use is a commonly-cited risk factor for SPs. One of the earliest studies to report this 
association was performed by Kearney et al., using a combined cohort of the Nurses' Health 
Study and Health Professionals Follow-up Study. Smoking was found to have a strong 
association with distal SPs in both men and women, (current vs. never smokers: males RR 
2.45, 95% CI 1.59, 3.75; females RR 1.96 95% CI 1.16, 2.86) [44]. A smaller study 
performed by Martinez et al. also reported that tobacco was associated with increased risk of 
SPs (current vs. never smokers: OR 2.10, 95% CI 1.12, 3.94) [41]. Other studies in larger 
populations, including US, German and Japanese patients have also provided evidence that 
smoking is a risk factor for distal SPs and SPs in general [33, 42, 43, 45, 46] (Table 3). Two 
contemporary studies also reported associations between smoking and SPs, including Fu et 
al. (current vs. never smokers: OR 4.44, 95% CI 3.47, 5.67) and Burnett-Hartman et al. 
(current vs. never smokers OR 3.00, 95% CI 1.93, 4.66) [48, 60] (Table 3).
While the evidence largely supports a positive association between smoking and risk of SPs 
in general, data on anatomical location are mixed. Using pooled data from three different 
polyp chemoprevention studies, Wallace et al. reported that smoking was associated with 
development of SPs in the distal colon, but not the proximal colon (current vs. never 
smokers: proximal colon RR 1.11 95% CI 0.80, 1.54; distal colon RR 2.18 95% CI 1.80, 
2.65) [52]. Burnett-Hartman found no correlation with tobacco use of 199 proximal SPs 
(current vs. never smokers OR 0.88 95% CI 0.32, 2.39) [48]. In contrast, Bouwens et al. did 
find an increased risk of large (>6 mm), proximal or dysplastic SPs associated with smoking 
(current vs. never smokers OR 2.2, 95% CI 1.4, 3.6) [51].
Several studies have examined the relationship of tobacco and SSAs or advanced SPs (Table 
3). Anderson et al. found a positive association with tobacco and SSAs (≥20 vs. <20 pack-
years OR 7.31, 95% CI 3.92, 13.63) [49]. In a slightly larger study, Burnett-Hartman et al. 
also reported an association between smoking and SSAs (current vs. never smokers OR 
2.91, 95% CI 1.36, 6.21) [48]. Wallace et al. found that tobacco use was associated with a 
significantly increased risk of advanced SPs in the distal colorectum, but not in the proximal 
colon (current vs. never smokers: proximal RR 1.51, 95% CI 0.80, 2.86; distal RR 3.42, 95% 
CI 1.91, 6.11) [52] (Supplementary Table 3). Given the somewhat discordant results 
regarding smoking in studies of proximal SPs (a high proportion of which are SSAs) and 
those of SSAs specifically, the role of smoking in serrated neoplasia remains somewhat 
uncertain.
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Alcohol use has been shown to increase risk of development of HP/SPs in a few early 
studies, as shown by Martinez et al. (>9.4 g/day vs. nonuse: OR 2.01, 95% CI 1.11, 3.63) 
and Kearney et al. (>30 g/day vs. nonuse: male RR 1.69, 95% CI 1.01, 2.80; female RR 
1.79, 95% CI 1.02, 3.15) [41, 44]. However, alcohol has generally not been found to be a 
risk factor for SPs in more contemporary studies of SPs [33, 42, 45, 46, 48, 60] 
(Supplementary Table 1).
With respect to more advanced SPs, 3 studies reported no association between alcohol and 
risk of proximal or large SPs [48, 51, 52] (Supplementary Table 2). Burnett-Hartman et al. 
reported that alcohol use was not associated with SSAs specifically (≥14 vs. <1 drinks/week: 
OR 1.09 95% CI 0.54, 2.20). Wallace et al. also reported lack of association between alcohol 
and advanced SPs (≥1 drink/day vs. nonuse: proximal RR 1.20 95% CI 0.73, 1.98; distal RR 
1.19 95% CI 0.73, 1.92) [48, 52] (Supplementary Table 3). Therefore, the relationship 
between alcohol and SPs in general is questionable, and there does not appear to be a strong 
association between alcohol use and advanced SPs or SSAs specifically.
Diet
There are several well-established relationships between certain dietary components and 
both conventional adenomas and CRC, such as higher intake of processed and red meat, 
refined carbohydrates, and lower intake of fruits and vegetables [16, 61]. The relationship 
between diet and SPs is less clear, but the few published studies examining the nutritional 
epidemiology of SPs will be reviewed below.
Macronutrients and specific foods—A positive association between red meat intake 
and SPs was reported in a recent colonoscopy-based case-control study by Fu and colleagues 
(≥44.2 vs. <10 g/day: OR 1.36, 95% CI 1.04, 1.78) while Erhardt et al. also found that high 
intake of meat (ham and sausage in particular), was associated with a higher prevalence of 
SPs in a German population (≥15 vs. <15 g/day: OR 3.70, 95% CI 1.49, 9.19) [42, 60] 
(Supplementary Table 1). Fu et al. failed to find a significant association of HPs with fiber 
intake or overall fat intake [60]. Kearney et al. similarly found that animal fat intake was not 
associated with SPs [44]. However, Wallace et al. reported that high fat diets were associated 
with SPs, including advanced lesions, at all anatomical sites (quartile 4 vs. quartile 1 fat 
intake, proximal SPs: RR 1.45 95% CI 1.01, 2.10; distal SPs RR 1.27 95% CI 1.03, 1.56; 
quartile 3 versus quartile 1 proximal advanced SPs: RR 2.38, 95% CI 1.24, 4.57; quartile 3 
versus quartile 1 distal advanced SPs: RR 1.86, 95% CI 1.02, 3.41) [52]. However, the 
authors did not find an association between red meat intake and SPs. High carbohydrate 
diets were not clearly associated with SPs in general or advanced SPs. High calorie diets 
were only associated with distal advanced SPs (quartile 4 vs. quartile 1 total energy intake: 
RR 2.28, 95% CI 1.23, 4.24). There were no specific foods or macronutrient categories that 
were associated with significant protective effects in these studies.
Micronutrients—An array of vitamin and mineral supplements have been analyzed in 
epidemiological studies of HPs, including vitamins D, E and C, beta-carotene, and 
multivitamin supplements, however, no conclusive evidence of a significant association has 
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been reported [33, 41, 44, 45]. Calcium has been shown to have an inverse association with 
SPs by Fu (≥1169.3 vs. ≤229.3 mg/day: OR 0.73, 95% CI 0.56, 0.96) and Martinez (≥1094 
vs. ≤558 mg/day: OR 0.41, 95% CI 0.19, 0.90) [41, 60]. Regarding folate intake, there were 
three studies that looked at its relationship to SPs. Kearney et al. found that female subjects 
taking higher doses of folate had decreased incidence of distal SPs (>672 vs. <280 vs. mcg/
day: RR 0.45, 95% CI 0.28, 0.74) [44]. Additionally, Fu et al. reported an inverse association 
with folate intake and SPs (≥584.4 vs. ≤421.4 mcg/day: OR 0.73, 95% CI 0.56, 0.96) [60] 
(Supplementary Table 1). Conversely, in the study performed by Wallace et al., folate was 
shown to actually increase the risk of proximal advanced SPs (1 mg folate daily vs. placebo: 
RR 2.07, 95% CI: 1.14, 3.77) [52] (Supplementary Table 3). This difference may have to do 
with the fact that supplemental folate was administered as an investigational chemo-
preventive agent in the Wallace study vs. dietary folate content in the Fu et al. and Nurses' 
Health studies. However, given these seemingly discordant results, the association between 
folate intake and SPs is not entirely clear, and merits further research.
Obesity
Obesity, assessed by elevated body mass index (BMI) is associated with increased incidence 
of both colorectal adenomas and CRC [62-65]. Regarding serrated pathway lesions, several 
studies show a direct relationship with obesity. Early studies showed an increased risk of 
HPs and SPs in general associated with higher BMI, as reported by Martinez et al. (BMI 
>29.8 vs. <23.4: OR 3.79, 95% CI 1.61, 8.92) and Morimoto (BMI 26.5-29.6 vs. <24.2: 
male OR 2.2, 95% CI 1.2, 4.3) [41, 45] (Table 4). Notably, in the Morimoto study, the 
relationship between obesity and SPs was limited to men, with an essentially null finding 
reported for women [45] Fu et al. also found a positive correlation between BMI and SPs 
(BMI ≥ 30 vs. 18.5-24.9: OR 1.36, 95% 1.08, 1.70). Later studies using contemporary 
criteria for SPs confirmed an association between higher BMI and distal, but not proximal 
SPs, as shown by Wallace (BMI ≥30 vs. <25: distal RR 1.27, 95% CI: 1.06, 1.53) and 
Burnett-Hartman (BMI ≥30 vs. <25: distal OR 1.48, 95% CI: 1.04, 2.11) (Table 4).
The association between obesity and SSAs specifically has been examined in two studies, 
with conflicting results. Anderson et al. found that obesity was associated with all SSAs 
(BMI ≥30 vs. <30: OR 2.57, 95% CI 1.44, 4.62) and large SSAs (≥ 1cm) in particular (OR 
3.96, 95% CI 1.27, 12.36) [49]. In contrast, Burnett-Hartman did not find an association 
between obesity and SSAs in a larger cohort, (BMI ≥30 vs. <25, OR 1.13, 95% CI: 0.66, 
1.94) [48].
Aspirin/NSAID use
A number of studies have examined the role of NSAIDs and aspirin in the epidemiology of 
SPs. Early studies did find a risk reduction of SPs in subjects who used NSAIDs, including 
Lieberman et al. (daily vs. never use: OR 0.75, 95% CI 0.56, 0.99) and Martinez et al. (use 
≥7 times/week vs. never use: OR 0.32, 95% CI 0.14, 0.72) [33, 41] (Table 5). Later studies 
performed by Bouwens et al. (nondaily or no use vs. daily aspirin use: OR 1.8, 95% CI: 1.1, 
3.0) and Wallace et al. (daily aspirin use vs. placebo: proximal RR 0.56, 95% CI 0.34, 0.91; 
distal RR 0.77, 95% CI 0.58, 1.04) found that aspirin use decreased risk of SPs, particularly 
in proximal lesions [51, 52]. Several studies have reported trends toward inverse associations 
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between NSAIDs and SSAs or advanced SPs specifically, but these estimates did not reach 
statistical significance, perhaps due to sample size limitations [48, 52] (Table 5 and 
Supplementary Table 3). Overall, evidence suggests that aspirin and NSAIDs may have a 
chemopreventive effect for proximal SPs (particularly SSAs), but further conclusive 
evidence is needed.
Family history
Family history of CRC is a major factor in cancer screening guidelines yet there have been 
mixed results regarding its implications on SPs [66]. Of the six studies that examined family 
history of CRC as a risk factor for SPs [25, 33, 44, 48, 49, 52], only two reported an 
association. Kearney et al. reported that family history of CRC was positively associated 
with SPs among both males (RR 1.95, 95% CI 1.39, 2.74) and females (RR 2.03, 95% CI 
1.39, 2.95) (Supplementary Table 1). Similarly, Spring et al. reported that patients with 
SSAs specifically may be more likely to have a family history of CRC, as 42% of patients 
with SSAs had a 1st degree relative with CRC, compared to 25% of controls, although this 
did not reach statistical significance [25]. Thus, while family history of CRC is an important 
risk factor in screening in general, its importance in development of SPs is at this point is 
unclear, and needs to be further elucidated. It is possible, for example, that persons with a 
“specific” family history of SPs or MSI-high CRC have an increased risk of developing 
SSAs. Along these lines, several studies have shown that relatives of persons with CRC with 
serrated pathway genetic alterations (e.g. BRAF mutation) do have an elevated risk of CRC 
[67, 68]. One would presume that those relatives are also at risk for serrated pathway 
precursor lesions (i.e. SSAs), but that has not been definitively shown. Also, it is clearly 
established that in patients with serrated polyposis syndrome (SPS), there is a heritable and 
genetic predisposition for developing SPs and serrated pathway cancers [69, 70].
Personal history of serrated lesions
It is well established that persons with a personal history of conventional adenomas have an 
increased risk of adenoma recurrence, and for this reason, post-polypectomy surveillance is 
recommended when adenomas are found [14, 71, 72]. With the exception of SPS 
populations, the risk of metachronous serrated neoplasia in those with SPs (and the 
importance of a prior history of SPs) has been less studied. With respect to SPs in general, 
Benson et al. reported that a history of SPs was associated with an increased risk of future 
SPs, but not adenomas (OR for SPs: 3.67, 95% CI 2.54, 5.31) [73]. Interestingly, having 
both HP and adenomas on the index exam was a stronger risk factor for having SPs and 
adenomas at follow up, compared to those with only one type of polyp on their index exam. 
Two other studies performed by Spring et al. and Burnett-Hartman et al. also found that a 
history of polyps was associated with SPs, however, these studies did not distinguish if the 
index polyps were conventional adenomas or SPs [25, 74]. Two contemporary studies 
addressed this question directly. Bouwens et al. reported that a personal history of SPs was 
an independent risk factor for finding a large, proximal, or dysplastic SP on follow-up 
colonoscopy (OR 2.6, 95% CI 1.3, 4.9) [51]. Additionally, Teriaky et al. reported that among 
22 patients with SSAs on index colonoscopy, 50% had a metachronous SSA during a 5 year 
follow-up period [75]. Therefore it appears that a history of SPs and SSAs specifically is a 
risk factor for future SPs.
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Physical activity—There is evidence that physical activity may have protective effects 
against conventional adenomas as well as CRC in both proximal and distal locations [76, 
77]. With respect to SPs, a similar protective effect has not been established, though this has 
been studied by several investigators [33, 41, 45, 48, 60] (Supplementary Tables 1-3).
Diabetes—Similarly, diabetes has been reported to be a possible risk factor for CRC and 
conventional adenomas [78, 79]. There are sparse data regarding the association between 
diabetes and SPs. Bouwens et al found no relation between diabetes and SPs, while 
Anderson et al. did report an association with SSAs in diabetics versus nondiabetics (OR 
4.57, 95% CI 2.36, 8.82) [49, 51] (Supplementary Table 3).
Hormone replacement therapy—Two studies have examined the role of hormone 
replacement therapy (HRT) in development of SPs, in analyses limited to women. Burnett-
Hartman et al. found that there was an inverse relationship in the use of estrogen-only HRT 
and development of SPs (OR 0.63, 95% CI: 0.44, 0.90). Morimoto reported a borderline 
association between ever use of HRT and SPs (OR 0.7, 95% CI 0.4, 1.1) [45]. Interestingly, 
these findings do seem to correlate with the protective effects of HRT against colorectal 
cancer as reported in 2004 by the Women's Health Initiative study [80]. As SSAs appear to 
be more common in women, the role of estrogen in the pathogenesis of serrated pathway 
lesions merits further research.
Risk Factors for Traditional Serrated Adenomas
Since TSAs are rare, there are scant epidemiologic data on these polyps. In the largest series 
of TSAs (n=709 patients), Lash et al. reported that the median age of those harboring TSAs 
was 63 years, and roughly half were women (50.9%) [26]. There was a trend towards higher 
risk of dysplasia associated with female sex, but this did not reach statistical significance 
(OR 1.83 (95% CI 0.48, 6.95). Some have suggested a connection between TSAs and 
inflammatory bowel disease, but this is inconclusive [81, 82].
Risk factors for specific genetic and epigenetic alterations
A variety of genetic mutations contribute to the pathway by which SPs develop and progress 
towards serrated carcinoma. While the studies reviewed previously have examined risk 
factors for histologic outcome of SPs, a few studies have identified risk factors for serrated 
pathway mutations as well. One study analyzed risk factors for BRAF mutations and CIMP-
high phenotypes, it was shown that BRAF mutations were associated with male sex (OR 
1.47 95% CI: 1.04, 2.09), BMI (≥30 vs. <25: OR 1.57 95% CI: 1.03, 2.40), tobacco use 
(current vs. never smoker OR 2.75 95% CI: 1.48, 5.11) and history of prior colorectal polyps 
(OR 1.60 95% CI: 1.11, 2.30), while CIMP-high was associated with Caucasian race (OR 
2.27 95% CI: 1.08, 4.76), tobacco use (current vs. never smoker OR 2.71 95% CI: 1.19, 
6.18) and history of prior colorectal polyps (OR 2.35 95% CI: 1.46, 3.79) [74]. These results 
are consistent with several of the risk factors for SPs identified above.
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There have been few established risk factors identified for SPs. Tobacco, alcohol, and 
obesity have been shown fairly consistently to be associated with increased risk of SPs in 
general [33, 41-46, 48, 49, 52]. There is also limited evidence that Caucasians and those 
with diets high in fat and calories have a greater risk of SPs [52]. Some data suggest that 
folate intake and NSAID use may serve a protective role against SPs, however results are 
somewhat mixed [48, 49, 52]. Estrogen-only HRT has also been associated with a protective 
effect against SPs [48]. With regards to SSAs specifically, the published risk factor research 
is limited. Female sex has been associated with SSAs in multiple studies [5, 24-26]. 
Smoking has also consistently been identified as a risk factor for SSAs [48, 49]. There have 
been mixed results involving obesity, as one study did find an association with SSAs [49], 
however, two others did not [48, 52]. Interestingly, one study found a relation between 
higher levels of education and SSAs [48]. Aspirin and NSAID use may have a protective 
effect, at least for proximal SPs, and probably for SSAs as well [48, 51, 52]. Even less data 
exists regarding the epidemiology of TSAs, and risk factors for these polyps are largely 
unknown. Given that SSAs and TSAs are understood to be precursors to a substantial 
proportion of sporadic CRC, more research is warranted to establish which populations are 
most prone to developing these polyps. While risk factors for SPs appear to overlap with 
those of conventional adenomas, there are some clear differences (Figure 2).
A major limitation in the epidemiology of SPs is related to the shift in pathological 
classification that has occurred over the past decade, as our understanding of the serrated 
pathway has developed. In early studies, SPs were not routinely differentiated between more 
benign HPs versus premalignant SSAs or TSAs, and as such, epidemiologic studies prior to 
the mid to late-2000s are largely limited by outdated pathological interpretations and 
terminology [33, 41, 43-46]. Furthermore, many of these studies focused solely on distal 
polyps (primarily small HPs), which are not thought to have malignant potential, limiting 
their clinical relevance [43, 44]. As such, it is difficult to interpret the findings from many 
prior studies of SPs, and we recognize that risk factors for polyps previously categorized 
under the (now outdated) umbrella term “hyperplastic polyps” may not be the same as risk 
factors for premalignant SPs. For these reasons, more contemporary studies are likely to be 
most informative with respect to the epidemiology of SPs. This review underscores the need 
for a reassessment of risk factors for all categories of SPs based on the current pathologic 
criteria and nomenclature, especially for SSAs, which have arguably the most relevance 
clinically in CRC screening given their premalignant potential and relative abundance with 
respect to TSAs.
As with the adenoma-carcinoma sequence, different risk factors may influence different 
steps of the serrated pathway (Figure 1). Also, it is clear that some persons have a genetic 
predisposition to serrated pathway polyps and cancers. In the prototypical case, this is 
manifest by SPS, a condition of multiple SPs and an increased risk of CRC [83]. While the 
specific genetic defects underlying this condition have yet to be elucidated, there is likely a 
continuum of risk associated with a number of genes (or epigenetic modifications) with 
some persons experiencing more attenuated phenotypes. Environmental risk factors likely 
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interact with a given person's genetic susceptibility [84]. Therefore, future epidemiologic 
research on SPs should take into account molecular aspects of these lesions as well [85].
In conclusion, the number of contemporary epidemiological studies on SPs is limited, and 
results have been mixed, with few established risk factors identified thus far. Given the 
increasingly recognized importance of SPs (and particularly SSAs) as CRC precursors, 
further research is needed on this topic [12]. Specifically, tobacco, folate, NSAIDs, sex, diet, 
HRT, and socioeconomic status are risk factors that merit further investigation. Rigorously 
conducted cross-sectional or case-control studies of patients undergoing high-quality 
colonoscopic screening examinations with expert gastrointestinal pathologist readings will 
provide the best evidence in this regard. Future studies should compare patients with SSAs 
to those conventional adenomas and negative colonoscopies, and ideally would further 
characterize SSAs by their specific genetic and epigenetic alterations. Compared to the 
adenoma-carcinoma sequence, the serrated pathway is relatively understudied, and therefore 
identification of risk factors is important not only for risk stratification, but also in order to 
better understand the cascade of events that lead to a serrated pathway cancer. A better 
understanding of the epidemiology of serrated neoplasia and its associated molecular defects 
is warranted in order to optimally impact screening and prevention of all sporadic CRC.
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The Serrated Pathways to colorectal cancer, with proposed sequence of mutations and 
alterations leading to serrated carcinomas, and potential steps that could be influenced by 
risk factors (red arrows). Dotted lines represent proposed but unproven steps. See text for 
definition of abbreviations. Adapted from Snover [22] and Huang [3]
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Established and probable risk factors for serrated and adenomatous colorectal polyps, and 
sessile serrated adenomas/proximal serrated polyps specifically, based on current literature. 
See text for definition of abbreviations.
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Table 1
Studies of serrated polyps and age
Author, year Study description n with SPs Age OR/RR* (95% CI)
All SPs
Erhardt, 2002 [42] German population Screening/diagnostic colonoscopy 71 ≤55 y: 1.00 [ref]>55 y: 1.72 (1.00-2.96)
Morimoto, 2002 [45] US population (MN) Screening/diagnostic colonoscopy 219
<40 y: 1.0 [ref]
40-49 y: 0.9 (0.4-2.3)
50-59 y: 1.6 (0.7-3.7)
60-69 y: 1.4 (0.6-3.2)
≥70 y: 1.6 (0.5-5.0)
Lieberman, 2003 [33] US population (veterans) Screening colonoscopy 391
50-54 y: 1.00 [ref]
55-59 y: 1.10 (0.76-1.60)
60-64 y: 1.05 (0.76-1.46)
65-69 y: 1.01 (0.72-1.41)
≥70 y: 0.70 (0.48-1.02)
Omata, 2009 [46] Japanese population, Diagnostic colonoscopy 132
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Screening colonoscopy 594
Proximal/large SPs
Wallace, 2009 [52] US population (multicenter/PPSG) Proximal SPs 261 <61 y: 1.00 [ref]≥61 y: 0.86 (0.68-1.10)




Bouwens, 2013 [51] Dutch population Proximal, large (>6mm) or dysplastic SPs 141
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Proximal SPs 199
<50 y: 1.00 [ref]
50-59 y: 1.49 (0.70-3.14)
60-69 y: 1.72 (0.77-3.85)
≥70 y: 1.51 (0.60-3.81)
SSAs
Anderson, 2011 [49] US population (CT) Pancolonic SSAs 90 Per year increase: 1.05 (1.02-1.08)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Pancolonic SSAs 149
<50 y: 1.00 [ref]
50-59 y: 1.63 (0.72-3.67)
60-69 y: 2.09 (0.87-5.00)
≥70 y: 2.19 (0.83-5.76)
Hetzel, 2010 [5] US population (Boston) Pancolonic SSAs 46 Per year increase†: 1.00 (0.96-1.03)
*
multivariate adjusted OR reported when provided
†
Incidence rate ratio
SP: serrated polyp; SSA: sessile serrated adenoma; OR: odds ratio; RR: risk ratio; CI: confidence interval; PPSG: Polyp Prevention study Group
Red text: statistically significant result
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Table 2
Studies of serrated polyps and sex
Author, year Study description n with SPs Sex OR/RR* (95% CI)
All SPs
Erhardt, 2002 [42]
German population Screening/diagnostic colonoscopy
71
Morimoto, 2002 [45]
US population (MN) Screening/diagnostic colonoscopy
219
Omata, 2009 [46] Japanese population Diagnostic colonoscopy 132 Female: 1.00 [ref]Male: 1.54 (0.97-2.44)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Screening colonoscopy 594 Male: 1.00 [ref]Female: 1.06 (0.80-1.40)
Proximal/large SPs
Wallace, 2009 [52] US population (multicenter/PPSG) Proximal SPs 261 Male: 1.00 [ref]Female: 1.07 (0.82-1.39)
Min, 2012 [56] Korean population Proximal SPs 60 Female: 1.00 [ref]Male: 1.82 (0.99-3.32)
Bouwens, 2013 [51] Dutch population Proximal, large (>6mm) or dysplastic SPs 141 Female: 1.0 [ref]Male: 0.9 (0.6-1.2)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Proximal SPs 199 Male: 1.00 [ref]Female: 1.05 (0.66-1.67)
SSAs
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Pancolonic SSAs 149 Male: 1.00 [ref]Female: 1.37 (0.82-2.28)
Lash, 2010 [26] US population (multicenter) Pancolonic SSAs 2416




multivariate adjusted OR reported when provided
†
Incidence rate ratio
SP: serrated polyp; SSA: sessile serrated adenoma; OR: odds ratio; RR: risk ratio; CI: confidence interval; PPSG: Polyp Prevention study Group
Red text: statistically significant result
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Table 3
Studies of serrated polyps and smoking
Author, year Study description n with SPs Smoking* OR/RR† (95% CI)
All SPs
Kearney, 1995 [44] US population (NHS/HPFS) Screening sigmoidoscopy or colonoscopy, distal HP/SP only 394
Martinez, 1997 [41] US population (TX) Screening sigmoidoscopy or colonoscopy 81
Erhardt, 2002 [42] German population Screening/diagnostic colonoscopy 71 Ever smoker: 1.79 (1.04-3.06)
Morimoto, 2002 [45] US population (MN) Screening/diagnostic colonoscopy 219 Former smoker: 2.5 (1.4-4.4)Current smoker: 4.1 (2.2-7.6)
Lieberman, 2003 [33] US population (veterans) Screening colonoscopy 391 Former smoker: 1.65 (1.23-2.23)Current smoker: 2.71 (1.93-3.81)
Ji, 2006 [43] US population (PLCO) Screening sigmoidoscopy, distal HP/SP only 1545
Former smoker: 1.8 (1.6-2.1)
Current smoker: 4.4 (3.7-5.2)
Ever smoker: 2.1 (1.9-2.4)
Omata, 2009 [46] Japanese population Diagnostic colonoscopy 132
Fu, 2012 [60] US population (TN) Screening/diagnostic colonoscopy 662
Former smoker: 1.93 (1.56-2.38)
Current smoker: 4.44 (3.47-5.67)
<30 pack-years: 4.74 (3.51-6.42)
≥30 pack-years: 4.04 (3.02-5.42)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Screening colonoscopy 594 Former smoker: 1.70 (1.34-2.16)Current smoker: 3.00 (1.93-4.66)
Proximal/large SPs
Wallace, 2009 [52] US population (multicenter/PPSG) Proximal SPs 261 Former smoker: 0.98 (0.75-1.28)Current smoker: 1.11 (0.80-1.54)
Bouwens, 2013 [51] Dutch population Proximal, large (>6mm) or dysplastic SPs 141
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Proximal SPs 199 Former smoker: 1.16 (0.79-1.71)Current smoker: 0.88 (0.32-2.39)
SSAs
Anderson, 2011 [49] US population (CT) Pancolonic SSAs 90
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Pancolonic SSAs 149
*
Referent category (OR/RR=1.0) is nonsmokers or never smokers for all studies unless otherwise stated
†
multivariate adjusted OR reported when provided
SP: serrated polyp; SSA: sessile serrated adenoma; OR: odds ratio; RR: risk ratio; CI: confidence interval; NHS/HPFS: Nurses Health Study/Health 
Professionals Followup Study; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PPSG: Polyp Prevention study Group
Red text: statistically significant result
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Table 4
Studies of serrated polyps and obesity
Author, year Study description n with SPs BMI OR/RR* (95% CI)
All SPs
Martinez, 1997 [41] US population (TX) Screening sigmoidoscopy or colonoscopy 81
Erhardt, 2002 [42] German population Screening/diagnostic colonoscopy 71 BMI ≤24: 1.00 [ref]BMI >24: 1.39 (0.79-2.46)
Morimoto, 2002 [45] US population (MN) Screening/diagnostic colonoscopy 219
Females
BMI <22.7: 1.0 [ref]
BMI 22.7-25.8: 0.8 (0.4-1.7)
BMI 25.9-29.8: 0.9 (0.5-1.7)
BMI ≥29.9: 1.1 (0.6-2.0)
Omata, 2009 [46] Japanese population Diagnostic colonoscopy 132
BMI <22: 1.00 [ref]
BMI ≥22: 1.51 (0.97-2.33)
BMI ≥25: 1.41 (0.81-2.44)
Fu, 2012 [60] US population (TN) Screening/diagnostic colonoscopy 662
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Screening colonoscopy 594
BMI <25: 1.00 [ref]
BMI 25-29: 0.97 (0.75-1.26)
BMI ≥30: 1.26 (0.93-1.71)
Proximal/large SPs
Wallace, 2009 [52] US population (multicenter/PPSG) Proximal SPs 261
BMI <25: 1.00 [ref]
BMI 25-29.9: 0.96 (0.73-1.27)
BMI ≥30: 1.13 (0.83-1.56)
Bouwens, 2013 [51] Dutch population Proximal, large (>6mm) or dysplastic SPs 141
BMI <25: 1.0 [ref]
BMI 25-29.9: 1.0 (0.7-1.5)
BMI ≥30: 1.4 (0.9-2.3)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Proximal SPs 199
BMI <25: 1.00 [ref]
BMI 25-29: 0.79 (0.53-1.20)
BMI ≥30: 0.71 (0.41-1.22)
SSAs
Anderson, 2011 [49] US population (CT) Pancolonic SSAs 90
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Pancolonic SSAs 149
BMI <25: 1.00 [ref]
BMI 25-29.9: 0.77 (0.48-1.23)
BMI ≥30: 1.13 (0.66-1.94)
*
multivariate adjusted OR reported when provided
SP: serrated polyp; SSA: sessile serrated adenoma; BMI: body mass index; OR: odds ratio; RR: risk ratio; CI: confidence interval; PPSG: Polyp 
Prevention study Group
Red text: statistically significant result
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Table 5
Studies of serrated polyps and nonsteroidal anti-inflammatory drug (NSAID) or aspirin 
usage
Author, year Study description n with SPs NSAID/ASA OR/RR* (95% CI)
All SPs
Martinez, 1997 [41] US population (TX) Screening sigmoidoscopy or colonoscopy 81
Morimoto, 2002 [45] US population (MN) Screening/diagnostic colonoscopy 219
Never use: 1.0 [ref]
≥once/week aspirin: 1.0 (0.6-1.6)
≥once/week NSAID: 0.6 (0.3-1.1)
Lieberman, 2003 [33] US population (veterans) Screening colonoscopy 391
Fu, 2012 [60] US population (TN) Screening/diagnostic colonoscopy 662
Never use: 1.00 [ref]
Former use: 0.96 (0.68-1.35)
Current Use: 0.84 (0.69-1.01)
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Screening colonoscopy 594
Nonuse: 1.00 [ref]
Former use: 0.89 (0.59-1.33)
Current use: 0.81 (0.64-1.03)
Proximal/large SPs
Wallace, 2009 [52] US population (multicenter/PPSG) Proximal SPs 261
Bouwens, 2013 [51] Dutch population Proximal, large (>6mm) or dysplastic SPs 141
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Proximal SPs 199
Nonuse: 1.00 [ref]
Former use: 1.21 (0.67-2.19)
Current use: 0.68 (0.46-1.03)
SSAs
Burnett-Hartman, 2013 [48] US population (Group Health, WA) Pancolonic SSAs 149
Nonuse: 1.00 [ref]
Former use: 1.39 (0.75-2.56)
Current use: 0.64 (0.41-1.01)
*
multivariate adjusted OR reported when provided
SP: serrated polyp; SSA: sessile serrated adenoma; BMI: body mass index; OR: odds ratio; RR: risk ratio; CI: confidence interval; PPSG: Polyp 
Prevention study Group
Red text: statistically significant result
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